mt-4561

Soft Tissue Sarcoma

Tanabe Pharma America, Inc.Phase 1/2Active

CC

45/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 33/ 100
Competitive Position: 81/ 100

Competitive context

103 Active assets in the Soft Tissue Sarcoma cohort.

Asset / Sponsor	Phase	Rating
Palbociclib Brown University	Phase 2	BB
FILGRASTIM University of California, Irvine	Phase 3	BB
Inno-206 GI Innovation, Inc.	Phase 3	BB
Eloxatin OHSU Knight Cancer Institute	Phase 2	BB
Cyclophosphamide St. Jude Children's Research Hospital	Phase 2	BB

View all 50 →

Same molecule, other indications

mt-4561 is also rated in:

neuroendocrine neoplasmDormant

CCC

Indicative ·

48 / 100

head and neck squamous cell carcinomaDormant

CC

Indicative ·

47 / 100

non-small cell lung carcinomaDormant

CC

Indicative ·

43 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.